Amisulpride

Amisulpride

Clinical data
Trade names	Solian
AHFS/Drugs.com	International Drug Names
Pregnancy category	AU: C
Routes of administration	Oral, IV
ATC code	N05AL05 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability	48%
Protein binding	16%
Metabolism	Hepatic (minimal; most excreted unchanged)
Biological half-life	12 hours
Excretion	Renal (23–46%),Fecal
Identifiers
IUPAC name 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide
CAS Number	71675-85-9 N
PubChem CID	2159
IUPHAR/BPS	963
DrugBank	DB06288 Y
ChemSpider	2074 Y
UNII	8110R61I4U
KEGG	D07310 Y
ChEBI	CHEBI:64045 N
ChEMBL	CHEMBL243712 Y
Chemical and physical data
Formula	C17H27N3O4S
Molar mass	369.48 g/mol
3D model (Jmol)	Interactive image
SMILES O=S(=O)(c1cc(c(OC)cc1N)C(=O)NCC2N(CC)CCC2)CC
InChI InChI=1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21) Y Key:NTJOBXMMWNYJFB-UHFFFAOYSA-N Y
NY (what is this?)

Amisulpride (sold as Amazeo, Amipride (AU), Amival, Solian (AU, IE, RU, UK, ZA), Soltus, Sulpitac (IN), Sulprix (AU), Socian (BR), is an atypical antipsychotic used to treat psychosis in schizophrenia and episodes of mania in bipolar disorder. In Italy, it is also used as a treatment for dysthymia.

It was introduced by Sanofi-Aventis in the 1990s. Its patent had expired by 2008 and hence generic formulations are now available.

It appears to have comparable efficacy to olanzapine in the treatment of schizophrenia. Amisulpride augmentation, similarly to sulpiride augmentation, has been considered a viable treatment option (although, it is worth noting that the supporting evidence is limited to the theory, case reports, a small randomised double-blind placebo-controlled trial and a couple of open-label studies) in clozapine-resistant cases of schizophrenia. A randomised, double-blind, placebo-controlled clinical trial has been conducted to evaluate the efficacy of celecoxib as an adjunct to amisulpride, with significant success. Another recent study concluded that amisulpride is an appropriate first-line treatment for the management of acute psychosis.

Amisulpride has been tried as a treatment for acute mania in a few open-label studies. These findings should be interpreted with caution, not just due to the fact that these clinical trials were all open-label and hence low-quality but also because several case reports have been made documenting the precipitation of mania in schizophrenia patients that received amisulpride.